Adam Maeder
Stock Analyst at Piper Sandler
(3.29)
# 1,009
Out of 5,165 analysts
102
Total ratings
46.67%
Success rate
3.52%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Adam Maeder
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RXST RxSight | Maintains: Neutral | $11 → $10 | $7.48 | +33.69% | 4 | Feb 26, 2026 | |
| TCMD Tactile Systems Technology | Maintains: Overweight | $35 → $42 | $27.30 | +53.85% | 6 | Feb 18, 2026 | |
| INSP Inspire Medical Systems | Maintains: Overweight | $165 → $85 | $58.87 | +44.39% | 18 | Feb 12, 2026 | |
| EW Edwards Lifesciences | Reiterates: Overweight | $98 → $100 | $83.56 | +19.67% | 19 | Feb 11, 2026 | |
| RMD ResMed | Maintains: Neutral | $270 → $275 | $230.61 | +19.25% | 5 | Jan 30, 2026 | |
| ISRG Intuitive Surgical | Maintains: Overweight | $610 → $620 | $483.46 | +28.24% | 22 | Jan 23, 2026 | |
| ABT Abbott Laboratories | Maintains: Overweight | $150 → $135 | $109.95 | +22.78% | 4 | Jan 23, 2026 | |
| SGHT Sight Sciences | Upgrades: Overweight | $5 → $9 | $3.74 | +140.64% | 3 | Jan 5, 2026 | |
| NYXH Nyxoah | Reiterates: Overweight | $12 → $9 | $3.15 | +185.71% | 9 | Nov 14, 2025 | |
| NSPR InspireMD | Maintains: Overweight | $4.5 → $4 | $1.64 | +144.65% | 4 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $20 → $21 | $17.09 | +22.88% | 2 | May 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 → $8 | $1.36 | +488.24% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $1.91 | +161.78% | 2 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $104 → $99 | $61.43 | +61.16% | 3 | May 5, 2022 |
RxSight
Feb 26, 2026
Maintains: Neutral
Price Target: $11 → $10
Current: $7.48
Upside: +33.69%
Tactile Systems Technology
Feb 18, 2026
Maintains: Overweight
Price Target: $35 → $42
Current: $27.30
Upside: +53.85%
Inspire Medical Systems
Feb 12, 2026
Maintains: Overweight
Price Target: $165 → $85
Current: $58.87
Upside: +44.39%
Edwards Lifesciences
Feb 11, 2026
Reiterates: Overweight
Price Target: $98 → $100
Current: $83.56
Upside: +19.67%
ResMed
Jan 30, 2026
Maintains: Neutral
Price Target: $270 → $275
Current: $230.61
Upside: +19.25%
Intuitive Surgical
Jan 23, 2026
Maintains: Overweight
Price Target: $610 → $620
Current: $483.46
Upside: +28.24%
Abbott Laboratories
Jan 23, 2026
Maintains: Overweight
Price Target: $150 → $135
Current: $109.95
Upside: +22.78%
Sight Sciences
Jan 5, 2026
Upgrades: Overweight
Price Target: $5 → $9
Current: $3.74
Upside: +140.64%
Nyxoah
Nov 14, 2025
Reiterates: Overweight
Price Target: $12 → $9
Current: $3.15
Upside: +185.71%
InspireMD
May 12, 2025
Maintains: Overweight
Price Target: $4.5 → $4
Current: $1.64
Upside: +144.65%
May 22, 2024
Maintains: Hold
Price Target: $20 → $21
Current: $17.09
Upside: +22.88%
Mar 6, 2024
Reiterates: Overweight
Price Target: $7 → $8
Current: $1.36
Upside: +488.24%
Mar 6, 2023
Maintains: Overweight
Price Target: $6 → $5
Current: $1.91
Upside: +161.78%
May 5, 2022
Maintains: Overweight
Price Target: $104 → $99
Current: $61.43
Upside: +61.16%